Taiyu Investment
- Company typePrivate
- Founded2014
- HeadquartersBeijing, China
- Headcount1–10
- GTM typeB2B
- OfferingServices
Taiyu Investment firmographics
Firmographics- Name
- Taiyu Investment
- Legal name
- Taiyu Investment (泰煜投资)
- Website
- https://tigeryeah.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Taiyu Investment industry classification
Industry- Product category
- Healthcare Venture Capital
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)
- akta.pro secondary industry
- Corporate Finance & Capital Advisory (BPAHADAB)
Keywords
Where Taiyu Investment is headquartered
LocationHeadquarters
- HQ city
- Beijing
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
Taiyu Investment business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Distribution channels1 record
Marketing channels2 records
Taiyu Investment product offering
Product offeringCore offering
Taiyu Investment is a healthcare-focused venture capital firm that manages seven RMB-denominated funds with over 20 billion RMB in total assets under management, primarily investing in early and growth-stage companies developing innovative medical devices, novel drugs, biotechnology, medical services, and nutrition health products. The firm also provides post-investment services including clinical and registration consulting, industry resource connections, and follow-on financing support to accelerate portfolio companies' commercialization. Since its 2014 founding, the firm has invested in more than 140-150 projects, with over 80% of investments placed at angel, Pre-A, and A round stages.
Product overview
Taiyu Investment is a venture capital firm (泰煜投资) that operates as a fund management platform rather than a traditional product company. Its core offering consists of investment fund management services across seven RMB funds, with over 20 billion RMB in assets under management. The company provides post-investment services to portfolio companies including clinical and registration consulting, financing support, and industry resource matching. The investment focus spans innovative medical devices, novel drugs, biotechnology, medical services, and nutrition health sectors.
Differentiator
Problem solved
Functional benefit
Products and services
- Healthcare Venture Capital Fund Management Management of seven RMB-denominated venture capital funds focused on early and growth-stage healthcare companies with strong innovation potential and core intellectual property, deploying over 20 billion RMB in total assets under management. The firm invests in innovative medical devices, novel drugs, biotechnology, medical services, and nutrition health, with over 80% of investments at angel, Pre-A, and A round stages.
- Post-Investment Support Services Comprehensive post-investment services for portfolio companies including connecting them with upstream and downstream industry customers, providing clinical and registration consulting to accelerate product market entry, and facilitating follow-on financing rounds. These services leverage the Tigermed CRO platform and the team's industry network.
Companies that use Taiyu Investment
Customer profileSegments1 record
Ideal customer profiles1 record
Taiyu Investment technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Taiyu Investment partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Tigermed (泰格医药)coreTigermed is the controlling shareholder and core investment platform of Taiyu Investment. This relationship provides access to clinical trial resources, regulatory expertise, industry network, and post-investment support capabilities for portfolio companies.
Scale indicators4 records
Recent moves14 records
Expansion highlights5 records
Taiyu Investment competitors and assessment
Company assessmentBroad incumbents
- CICC Capital (中金资本): Investment arm of China International Capital Corporation with diversified PE/VC funds including healthcare exposure. Comparable Chinese institutional investor profile but with broader mandate.
- CDH Investments (鼎晖投资): One of China's largest alternative asset managers with broad sector exposure including a sizable healthcare practice. Comparable as a major Chinese LP-style investor in healthcare but less specialized than Taiyu.
- Hillhouse Capital (高瓴资本): Asia-focused investment manager with a notable healthcare/biotech franchise. Comparable Chinese AUM scale but with broader sector mandate than Taiyu's healthcare-only focus.
- Sequoia Capital China (红杉中国): Major Chinese VC with broad sector coverage including a substantial healthcare practice. Comparable as a large-scale Chinese VC but healthcare is one of several verticals, not a sole focus like Taiyu.
Direct peers
- OrbiMed Advisors: Global healthcare-dedicated investment firm active across venture, growth, and public stages. Recurring co-investor with Taiyu (e.g., Zhitai Biotech Series C) and directly comparable on healthcare-only investment mandate.
- Qiming Venture Partners (启明创投): Leading Chinese VC with one of the largest healthcare practices, frequently co-investing alongside Taiyu (e.g., Zhitai Biotech Series C). Directly comparable on healthcare investment mandate and early-stage Chinese focus.
- Legend Capital (君联资本): Chinese PE/VC firm with a dedicated healthcare team investing across innovative drugs, devices, and diagnostics. Comparable stage range and sector focus to Taiyu.
- Highlight Capital (弘晖资本): China-focused healthcare VC firm investing in medical devices, biopharma, and digital health across early and growth stages. Closest comparable to Taiyu given similar sector focus, stage profile, and Chinese AUM scale.
- Lake Bleu Capital (清池资本): Hong Kong-based healthcare-focused public and private investment manager with deep China exposure. Comparable to Taiyu in healthcare sector specialization and Chinese biopharma/medical-device deal flow.
- Lilly Asia Ventures (礼来亚洲基金): Asia-focused healthcare VC with significant China presence investing in innovative drugs, devices, and diagnostics. Comparable as a healthcare-only specialist VC operating across similar early-stage rounds in China.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Taiyu Investment financial estimates
Financial estimateRevenue estimate
Valuation estimate
Taiyu Investment leadership team
Management profileNumber of profiles
Profiles14 records
Taiyu Investment funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Taiyu Investment M&A and investment
M&A and investmentM&A
Investments48 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Taiyu Investment
What does Taiyu Investment do?
Taiyu Investment is a healthcare-focused venture capital firm that manages seven RMB-denominated funds with over 20 billion RMB in total assets under management, primarily investing in early and growth-stage companies developing innovative medical devices, novel drugs, biotechnology, medical services, and nutrition health products. The firm also provides post-investment services including clinical and registration consulting, industry resource connections, and follow-on financing support to accelerate portfolio companies' commercialization. Since its 2014 founding, the firm has invested in more than 140-150 projects, with over 80% of investments placed at angel, Pre-A, and A round stages.
Is Taiyu Investment a public or private company?
Taiyu Investment is a private company. It is classified as corporate owned and is currently operating.
When was Taiyu Investment founded?
Taiyu Investment was founded in 2014. It employs 1 to 10 people.
Where is Taiyu Investment based?
Taiyu Investment is headquartered in Beijing, China, in the Asia region.
Who are Taiyu Investment's main competitors?
Broad incumbents on record are CICC Capital (中金资本), CDH Investments (鼎晖投资), Hillhouse Capital (高瓴资本) and Sequoia Capital China (红杉中国). Direct peers are OrbiMed Advisors, Qiming Venture Partners (启明创投), Legend Capital (君联资本), Highlight Capital (弘晖资本), Lake Bleu Capital (清池资本) and Lilly Asia Ventures (礼来亚洲基金).
Does Taiyu Investment have an API?
No public API is recorded for Taiyu Investment.
What industry is Taiyu Investment in?
Taiyu Investment's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAHAN, Corporate Strategic Real Assets & Infrastructure Venture Investing, with a secondary code of BPAHADAB, Corporate Finance & Capital Advisory. Its SIC code is 6282.